Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs

J. Szebeni, Gert Storm

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Liposomes are known to activate the complement (C) system, which can lead in vivo to a hypersensitivity syndrome called C activation-related pseudoallergy (CARPA). CARPA has been getting increasing attention as a safety risk of i.v. therapy with liposomes, whose testing is now recommended in bioequivalence evaluations of generic liposomal drug candidates. This review highlights the adverse consequences of C activation, the unique symptoms of CARPA triggered by essentially all i.v. administered liposomal drugs, and the various features of vesicles influencing this adverse immune effect. For the case of Doxil, we also address the mechanism of C activation and the opsonization vs. long circulation (stealth) paradox. In reviewing the methods of assessing C activation and CARPA, we delineate the most sensitive porcine model and an algorithm for stepwise evaluation of the CARPA risk of i.v. liposomes, which are proposed for standardization for preclinical toxicology evaluation of liposomal and other nanoparticulate drug candidates.

Original languageEnglish
Pages (from-to)490-497
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume468
Issue number3
DOIs
Publication statusPublished - Dec 18 2015

Fingerprint

Therapeutic Equivalency
Complement Activation
Liposomes
Chemical activation
Pharmaceutical Preparations
Generic Drugs
Toxicology
Hypersensitivity
Swine
Safety
Standardization
Therapeutics
Testing

Keywords

  • Adverse drug reactions
  • Anaphylatoxins
  • Anaphylaxis
  • C5a
  • Complement
  • Pigs
  • Pseudoallergy

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

@article{162edf9fb81d4c7794dc47990fea9d9c,
title = "Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs",
abstract = "Liposomes are known to activate the complement (C) system, which can lead in vivo to a hypersensitivity syndrome called C activation-related pseudoallergy (CARPA). CARPA has been getting increasing attention as a safety risk of i.v. therapy with liposomes, whose testing is now recommended in bioequivalence evaluations of generic liposomal drug candidates. This review highlights the adverse consequences of C activation, the unique symptoms of CARPA triggered by essentially all i.v. administered liposomal drugs, and the various features of vesicles influencing this adverse immune effect. For the case of Doxil, we also address the mechanism of C activation and the opsonization vs. long circulation (stealth) paradox. In reviewing the methods of assessing C activation and CARPA, we delineate the most sensitive porcine model and an algorithm for stepwise evaluation of the CARPA risk of i.v. liposomes, which are proposed for standardization for preclinical toxicology evaluation of liposomal and other nanoparticulate drug candidates.",
keywords = "Adverse drug reactions, Anaphylatoxins, Anaphylaxis, C5a, Complement, Pigs, Pseudoallergy",
author = "J. Szebeni and Gert Storm",
year = "2015",
month = "12",
day = "18",
doi = "10.1016/j.bbrc.2015.06.177",
language = "English",
volume = "468",
pages = "490--497",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs

AU - Szebeni, J.

AU - Storm, Gert

PY - 2015/12/18

Y1 - 2015/12/18

N2 - Liposomes are known to activate the complement (C) system, which can lead in vivo to a hypersensitivity syndrome called C activation-related pseudoallergy (CARPA). CARPA has been getting increasing attention as a safety risk of i.v. therapy with liposomes, whose testing is now recommended in bioequivalence evaluations of generic liposomal drug candidates. This review highlights the adverse consequences of C activation, the unique symptoms of CARPA triggered by essentially all i.v. administered liposomal drugs, and the various features of vesicles influencing this adverse immune effect. For the case of Doxil, we also address the mechanism of C activation and the opsonization vs. long circulation (stealth) paradox. In reviewing the methods of assessing C activation and CARPA, we delineate the most sensitive porcine model and an algorithm for stepwise evaluation of the CARPA risk of i.v. liposomes, which are proposed for standardization for preclinical toxicology evaluation of liposomal and other nanoparticulate drug candidates.

AB - Liposomes are known to activate the complement (C) system, which can lead in vivo to a hypersensitivity syndrome called C activation-related pseudoallergy (CARPA). CARPA has been getting increasing attention as a safety risk of i.v. therapy with liposomes, whose testing is now recommended in bioequivalence evaluations of generic liposomal drug candidates. This review highlights the adverse consequences of C activation, the unique symptoms of CARPA triggered by essentially all i.v. administered liposomal drugs, and the various features of vesicles influencing this adverse immune effect. For the case of Doxil, we also address the mechanism of C activation and the opsonization vs. long circulation (stealth) paradox. In reviewing the methods of assessing C activation and CARPA, we delineate the most sensitive porcine model and an algorithm for stepwise evaluation of the CARPA risk of i.v. liposomes, which are proposed for standardization for preclinical toxicology evaluation of liposomal and other nanoparticulate drug candidates.

KW - Adverse drug reactions

KW - Anaphylatoxins

KW - Anaphylaxis

KW - C5a

KW - Complement

KW - Pigs

KW - Pseudoallergy

UR - http://www.scopus.com/inward/record.url?scp=84951569729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951569729&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2015.06.177

DO - 10.1016/j.bbrc.2015.06.177

M3 - Article

VL - 468

SP - 490

EP - 497

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -